SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New lupus drug shows promise in Mid-Stage trial
Disease control Not yet recruitingThis study tests a new medicine called TQH3906 in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The goal is to see if the drug can reduce lupus activity and improve symptoms better than a placebo. About 198 adults with SLE will take either TQH3906 …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:26 UTC
-
New lupus drug MIL62 enters final testing phase
Disease control Not yet recruitingThis study tests a new medicine called MIL62 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The goal is to see if MIL62 can reduce lupus activity and allow lower steroid use compared to a placebo. About 316 adults with active lupus will take par…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:25 UTC
-
Could immune reset with donor CAR T-Cells tame lupus?
Disease control Not yet recruitingThis early-phase study tests a universal (donor-derived) CAR T-cell therapy called QT-019C in 15 adults with lupus or inflammatory myositis that has not responded to standard treatments. The therapy targets two immune-cell markers (CD19 and BCMA) to reset the faulty immune system…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated May 01, 2026 15:24 UTC
-
New hope for lupus: study tests Once-Weekly shot to tame the disease
Disease control Not yet recruitingThis study tests a once-weekly injection of anifrolumab in 245 adults with lupus who have not used other strong medications like immunosuppressants or biologics. The goal is to see if this treatment can help patients reach remission and reduce or stop their use of steroids. Parti…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New cell therapy aims to tame lupus and scleroderma
Disease control Not yet recruitingThis early study tests a new treatment called HN2302 in 12 adults with autoimmune diseases like lupus or scleroderma. The main goal is to check if it is safe and to see how the body makes special immune cells to fight the disease. It is a first step to find out if this approach c…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Personalized diet study aims to tame lupus flares
Disease control Not yet recruitingThis study tests whether a diet tailored to a person's genetic makeup can help manage lupus (SLE) and improve quality of life. Researchers will screen 100 adults with lupus for specific genes (HLA DQ2 and DQ8) and then assign those with the genes to either a personalized diet or …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: NA • Sponsor: Indonesia University • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Personalized dosing may boost lupus kidney treatment success
Disease control Not yet recruitingThis study looks at whether adjusting the dose of an immunosuppressant drug (mycophenolate mofetil) based on regular blood tests can help more people with lupus-related kidney disease achieve remission. About 100 adults with active lupus nephritis will be split into two groups: o…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: NA • Sponsor: Federal University of Maranhao • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus kidney disease
Disease control Not yet recruitingThis early study tests a new treatment called CHT105 for people with lupus nephritis that hasn't responded to standard therapies. CHT105 uses specially engineered immune cells from healthy donors to target and destroy the faulty immune cells driving the disease. The main goals ar…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: NA • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
Lupus drug showdown: which treatment works best?
Disease control Not yet recruitingThis study compares two drugs, telitacicept and belimumab, for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. Researchers want to see which drug better controls lupus symptoms and kidney problems. About 180 adults aged 18-65 will choose their treatm…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Sponsor: Yipeng Liu • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
500 volunteers help unlock secrets of autoimmune diseases
Knowledge-focused Not yet recruitingThis study collects medical information and biological samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will analyze blood and tissue samples to find patterns that could improve diagnosis and und…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated May 01, 2026 15:38 UTC